The era of precision medicine in neurology is rapidly approaching as a number of trials targeting specific genetic cohorts in Parkinson’s disease will soon be entering phase three clinical trial. However, there is a growing suspicion that these precision medicine therapies might not be precise enough and that if we are going to realize the promise that it has to offer we may need to take a bold jump straight to the next phase, super precision medicine…
